Title: Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Pro-drug Conversion
نویسندگان
چکیده
Title: Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor pro-drug conversion Authors: *Ashish V. Kalra, *Jaeyeon Kim, Stephan G. Klinz, Nancy Paz, Jason Cain, Daryl C. Drummond, Ulrik B. Nielsen, Jonathan B. Fitzgerald Authors Affiliation: Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts Running Title: nal-IRI activity depends on CPT-11 deposition and activation
منابع مشابه
Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
A major challenge in the clinical use of cytotoxic chemotherapeutics is maximizing efficacy in tumors while sparing normal tissue. Irinotecan is used for colorectal cancer treatment but the extent of its use is limited by toxic side effects. Liposomal delivery systems offer tools to modify pharmacokinetic and safety profiles of cytotoxic drugs. In this study, we defined parameters that maximize...
متن کاملComparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
BACKGROUND Liposomal drug packaging is well established as an effective means for increasing drug half-life, sustaining drug activity, and increasing drug efficacy, whether administered locally or distally to the site of disease. However, information regarding the relative effectiveness of peripheral (distal) versus local administration of liposomal therapeutics is limited. This issue is of imp...
متن کاملCancer Therapy: Preclinical Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal irinotecan (nal-IRI). Experimental Design: Mouse plasma and tissue pharmacokinetics of nal-IRI and the current clinical formulation of irinotecan were characterized. In vivo activity of irinotecan and nal-IRI was compared in xenograft models (3 each in nu/nu mice) of Ewing...
متن کاملNanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
Nanoliposomal irinotecan (nal-IRI) was originally developed using an efficient and high-loading capacity system to encapsulate irinotecan within a liposomal carrier, producing a therapeutic agent with improved biodistribution and pharmacokinetic characteristics compared to free drug. Specifically, administration of nal-IRI results in prolonged exposure of SN-38, the active metabolite of irinote...
متن کاملDevelopment of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.
Liposome formulations of camptothecins have been actively pursued because of the potential for significant pharmacologic advantages from successful drug delivery of this important class of anticancer drugs. We describe nanoliposomal CPT-11, a novel nanoparticle/liposome construct containing CPT-11 (irinotecan) with unprecedented drug loading efficiency and in vivo drug retention. Using a modifi...
متن کامل